Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
Last Updated: Monday, August 15, 2022
A prospective randomized, multicenter, phase 3 trial found that posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A found that PT-Cy after nonmyeloablative-matched allo-HSCT led to greater survival without severe GvHD.
Advertisement
News & Literature Highlights